James Forbes Acquires 5,000 Shares of DENTSPLY SIRONA (NASDAQ:XRAY) Stock

Key Points

• Insider purchase: Director James Forbes bought 5,000 shares on March 9 at an average price of $12.48, doubling his stake to 10,000 shares (acquisition value $62,400), as disclosed in an SEC Form 4.
• Recent results and guidance: DENTSPLY SIRONA reported quarterly EPS of $0.27 (missed by $0.01) with revenue of $961 million (+6.2% YoY) and set FY2026 guidance of $1.40–$1.50 EPS while analysts average ~1.84 EPS for the year.
• Market and payout profile: Shares traded near $12.80 with a $2.56 billion market cap and a negative PE (-4.27), and the company pays a quarterly dividend of $0.16 (annualized yield ~5.0%).

DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Get Free Report) Director James Forbes acquired 5,000 shares of the firm's stock in a transaction that occurred on Monday, March 9th. The shares were bought at an average price of $12.48 per share, with a total value of $62,400.00. Following the acquisition, the director directly owned 10,000 shares in the company, valued at $124,800. This represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

DENTSPLY SIRONA Trading Up 0.5%

XRAY stock traded up $0.06 during mid-day trading on Monday, reaching $12.80. The company had a trading volume of 3,590,577 shares, compared to its average volume of 4,989,556. The company has a market capitalization of $2.56 billion, a PE ratio of -4.27, a price-to-earnings-growth ratio of 1.49 and a beta of 0.97. The firm has a 50 day moving average of $12.63 and a 200 day moving average of $12.45. DENTSPLY SIRONA Inc. has a 12 month low of $9.85 and a 12 month high of $17.18. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The firm had revenue of $961.00 million during the quarter, compared to analysts' expectations of $926.40 million. During the same quarter in the previous year, the firm posted $0.26 EPS. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities analysts predict that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were issued a $0.16 dividend. The ex-dividend date was Friday, December 26th. This represents a $0.64 annualized dividend and a dividend yield of 5.0%. DENTSPLY SIRONA's payout ratio is currently -21.33%.

Institutional Trading of DENTSPLY SIRONA

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Parkside Financial Bank & Trust raised its holdings in DENTSPLY SIRONA by 620.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier's stock valued at $27,000 after acquiring an additional 1,477 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of DENTSPLY SIRONA during the 1st quarter worth approximately $26,000. Eurizon Capital SGR S.p.A. purchased a new stake in shares of DENTSPLY SIRONA in the fourth quarter valued at approximately $26,000. True Wealth Design LLC grew its position in shares of DENTSPLY SIRONA by 273.0% in the second quarter. True Wealth Design LLC now owns 2,376 shares of the medical instruments supplier's stock valued at $38,000 after purchasing an additional 1,739 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of DENTSPLY SIRONA by 337.9% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier's stock valued at $35,000 after purchasing an additional 2,122 shares during the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on XRAY. Bank of America raised shares of DENTSPLY SIRONA from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $13.00 to $17.00 in a report on Thursday, February 19th. Zacks Research upgraded DENTSPLY SIRONA from a "strong sell" rating to a "hold" rating in a report on Monday, March 2nd. Wells Fargo & Company lifted their price target on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an "equal weight" rating in a report on Friday, February 27th. Robert W. Baird boosted their price target on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a "neutral" rating in a research report on Friday, February 27th. Finally, Barclays began coverage on DENTSPLY SIRONA in a report on Monday, December 8th. They issued an "underweight" rating and a $12.00 price target for the company. Three investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $14.42.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.